

7231 Parkway Drive, Suite 100, Hanover, MD 21076

## Fax Completed Form and Applicable Progress Notes to: (410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

To be completed by requesting	o be completed by requesting provider		
Drug Name:	Strength:		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

ер	Please complete patient and physician information (please print):					
1			hysician Name:			
			Address:			
			Phone #:			
			Secure Fax #:			
Step 2	Please complete the clinical assessment:					
	1. Will the requested medication be used as dual therapy with Amitiza, Trulance, Symproic, Relistor, or Movantik? How old is the patient?		′ □ Yes	□ No		
			STOP	Proceed to question 2		
			Coverage not approved			
	2. He the notions received this modification and design					
	2. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Linzess		☐ Yes	□ No		
			(subject to verification)	Skip to question 4		
			Proceed to question 3			
	3. Has there been improvement in constipation symptoms?		□ Yes	□ No		
			Sign and date below	STOP		
				Coverage not approve		
	4. How old is the patient?		☐ Greater than or equal to 18 years of age - Proceed to question 5			
			☐ Greater than or equal to 6 years of age and Less than or equal to 17 years of age - Proceed to question 11			
			☐ Less than 6 years of age - STOP Coverage not approved			
	5. What is the ☐ IBS-C (Irritable Bowel Syndrome		e with Constipation) - Proceed to question <b>7</b>			
	indication or diagnosis? □ CIC (chronic idiopathic constip	ation) - Proceed to question 7				
	☐ OIC (opioid induced constipation question 6		on) in adults with chronic non-cancer pain - Proceed to			
			approved			

	6. Is the patient currently taking an opioid?	□ Yes	□ No
		Proceed to question 7	STOP
			Coverage not approved
	7. Does the patient have documented symptoms for greater than or equal to 3 months?	□ Yes	□ No
		Proceed to question 8	STOP
			Coverage not approved
	8. Does the patient have documentation of failure with an increase in dietary fiber/dietary modification to relieve symptoms?	□ Yes	□ No
		Proceed to question 9	STOP
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Coverage not approved
	9. Does the patient have gastrointestinal obstruction?	□ Yes	□ No
		STOP	Proceed to question <b>10</b>
		Coverage not approved	1 Tocced to question 10
	10. Has the patient tried and failed, has an intolerance or		
	FDA-labeled contraindication to at least 2 standard	☐ Yes	□ No
	laxative classes, defined as; <ul><li>osmotic laxative (for example, lactulose, sorbitol</li></ul>	Sign and date below	STOP
	magnesium [Mg] citrate, Mg hydroxide, glycerin rectal suppositories)		Coverage not approved
	<ul> <li>bulk forming laxative (for example, psyllium, oxidized cellulose, calcium polycarbophil) with fluids</li> </ul>		
	stool softener (for example, docusate)		
	stimulant laxative (for example, bisacodyl sennosides)		
	11. Does the patient have a diagnosis of functional constipation (FC)?	□ Yes	□ No
		Proceed to question 12	STOP
			Coverage not approved
	12. Does the patient have documented symptoms for	□ Yes	□ No
	greater than or equal to 3 months?	Proceed to question 13	STOP
			Coverage not approved
	13. Has the patient tried and failed, or had an intolerance	□ Yes	□ No
	or FDA-labeled contraindication to at least 2 of these agents: lactulose, sorbitol, senna, bisacodyl, glycerin	Sign and date below	STOP
	suppositories, or polyethylene glycol 3350?		Coverage not approved
Step 3	I certify the above is true to the best of my knowled	edge. Please sign and da	te:
-	Prescriber Signature	 Date	
			[22 Sep 2023]
For Inte	ernal Use Only		
Appro	oved:	Duration of Approval:	month(s)
☐ Denie	ed:	Authorized By:	
Incon	mplete/Other:	PA#:	
Date Fa	xed to MD:	Date Decision Rendered:	
		Date Decision Rendered.	